These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10752047)

  • 1. HIV-related lipodystrophy: a clinical syndrome with implications for nursing practice.
    Lyon DE; Truban E
    J Assoc Nurses AIDS Care; 2000; 11(2):36-42; quiz 43-6. PubMed ID: 10752047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of HIV-associated lipodystrophy.
    Wanke C
    AIDS Clin Care; 2000 Dec; 12(12):100. PubMed ID: 12211161
    [No Abstract]   [Full Text] [Related]  

  • 3. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buffalo hump: what the experts suggest.
    Piliero PJ; McComsey GA
    AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294
    [No Abstract]   [Full Text] [Related]  

  • 5. Getting to the HAART of insulin resistance.
    Nolan D; Mallal S
    AIDS; 2001 Oct; 15(15):2037-41. PubMed ID: 11600834
    [No Abstract]   [Full Text] [Related]  

  • 6. [Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
    Dieleman JP; Hillebrand-Haverkort ME; van der Ende ME; Sturkenboom MC; Lange JM; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Dec; 142(52):2856-60. PubMed ID: 10065260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.
    Heath KV; Hogg RS; Chan KJ; Harris M; Montessori V; O'Shaughnessy MV; Montanera JS
    AIDS; 2001 Jan; 15(2):231-9. PubMed ID: 11216932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy.
    Smith D
    J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HAART-associated body habitus and metabolic changes, Part 1.
    Liss M; Boyle BA
    AIDS Read; 2000 Nov; 10(11):622, 629-31. PubMed ID: 11186180
    [No Abstract]   [Full Text] [Related]  

  • 11. The latest word on lipodystrophy and mitochondrial toxicity (and old words that still resound).
    Mascolini M
    IAPAC Mon; 2002 Jan; 8(1):14-32. PubMed ID: 11858198
    [No Abstract]   [Full Text] [Related]  

  • 12. Substitution for protease inhibitors in HIV therapy.
    Mikhail E
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.
    Hansen BR; Haugaard SB; Iversen J; Nielsen JO; Andersen O
    Scand J Infect Dis; 2004; 36(4):244-53. PubMed ID: 15198179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
    Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
    Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.
    Heath KV; Hogg RS; Singer J; Chan KJ; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):440-7. PubMed ID: 12138351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wasting and body changes: what do we know so far?
    Gomez E
    Newsline People AIDS Coalit N Y; 1998 Sep; ():34-6. PubMed ID: 11367489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the trail of fugitive fat: the chase turns to NRTIs.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):24-43. PubMed ID: 11366871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV agents. Leading to lipodystrophy.
    TreatmentUpdate; 2007 Feb; 19(2):3-4. PubMed ID: 17447312
    [No Abstract]   [Full Text] [Related]  

  • 19. The HIV-associated lipodystrophy syndrome: research, results, yet more questions.
    Gharakhanian S
    AIDS; 2001 Jan; 15(2):271-3. PubMed ID: 11216938
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.